251303-04-5

Basic information

• Product Name: (2R)-2-[4-(9-bromo-2,3-dimethylnaphtho[2,3-b]thiophen-4-yl)-2,6-dimethylphenoxy]-3-phenylpropanoic acid
• Synonyms: benzenepropanoic acid, alpha-[4-(9-bromo-2,3-dimethylnaphtho[2,3-b]thien-4-yl)-2,6-dimethylphenoxy]-, (alphaR)-
• CAS NO: 251303-04-5
• Molecular Formula: C₃₁H₂₇BrO₃S
• Molecular Weight: 559.5133
• Mol File: 251303-04-5.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 690.7°C at 760 mmHg
• Flash Point: 371.5°C
• Density: 1.376g/cm³
• Vapor Pressure: 4.95E-20mmHg at 25°C
• Refractive Index: 1.681
• CAS DataBase Reference: (2R)-2-[4-(9-bromo-2,3-dimethylnaphtho[2,3-b]thiophen-4-yl)-2,6-dimethylphenoxy]-3-phenylpropanoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (2R)-2-[4-(9-bromo-2,3-dimethylnaphtho[2,3-b]thiophen-4-yl)-2,6-dimethylphenoxy]-3-phenylpropanoic acid(251303-04-5)
• EPA Substance Registry System: (2R)-2-[4-(9-bromo-2,3-dimethylnaphtho[2,3-b]thiophen-4-yl)-2,6-dimethylphenoxy]-3-phenylpropanoic acid(251303-04-5)

Safety Data

• Hazardous Substances Data: 251303-04-5(Hazardous Substances Data)

Usage

General Description

The chemical (2R)-2-[4-(9-bromo-2,3-dimethylnaphtho[2,3-b]thiophen-4-yl)-2,6-dimethylphenoxy]-3-phenylpropanoic acid is a complex organic compound with a long, multi-part name. It contains a carboxylic acid group, as indicated by the "propanoic acid" ending. The chemical structure also includes a phenyl group and multiple branches of methyl groups, as well as a bromine atom. The compound has a chiral center, as indicated by the (2R) designation, meaning it exists in two different mirroring forms. (2R)-2-[4-(9-bromo-2,3-dimethylnaphtho[2,3-b]thiophen-4-yl)-2,6-dimethylphenoxy]-3-phenylpropanoic acid may have potential applications in pharmaceuticals, medicinal chemistry, or other industries, as its specific structure and properties could be valuable for various purposes.

Upstream product

• 13673-95-5 (S)-methyl 2-hydroxy-3-phenylpropanoate 
• 250609-36-0 4-(2,3-dimethyl-naphtho[2,3-b]thiophen-4-yl)-2,6-dimethyl-phenol 

Relevant articles and documents

Chiral preparation method of Ertiprotafib

The invention relates to a synthesis method of Ertiprotafib shown in a formula (4). The method comprises specific steps as follows: a compound 1 shown in a formula (1) and L-phenyllactic acid methylester are subjected to a Mitsnobu reaction, and a compound 2 shown in a formula (2) is obtained; the compound 2 shown in the formula (2) is subjected to a bromination reaction, and a compound 3 shown in a formula (3) is obtained; the compound 3 shown in the formula (3) is hydrolyzed under the alkaline condition, and a final product, namely, Ertiprotafib, shown in a formula (4) is obtained. The method adopts a concise route, is simple and convenient to operate, high in stereoselectivity, good in chemoselectivity and environment-friendly, and a new method and thought are provided for preparation and production of the drug.

PTPase inhibitors for improving cardiovascular risk profile

-

Methods using PTPase inhibitors and insulin

This invention provides methods for utilizing a PTPase inhibiting compounds and one or more insulins in methods for use in control and maintenance of type II diabetes in a mammal, for improving the cardiovascular and cerebrovascular risk profiles, reduction of hyperlipidemia, lowering low density lipoprotein blood levels, lowering free fatty acid blood levels and triglyceride levels and inhibition, prevention or reduction of atherosclerosis in a type II diabetic, or the risk factors thereof.